Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Queensland Health
AstraZeneca
Deloitte
US Department of Justice
Medtronic
Federal Trade Commission
UBS
Citi

Generated: April 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,333,045

« Back to Dashboard

Which drugs does patent 6,333,045 protect, and when does it expire?

Patent 6,333,045 protects ZYMAR and is included in one NDA.

Protection for ZYMAR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has eighteen patent family members in sixteen countries.
Summary for Patent: 6,333,045
Title: Aqueous liquid pharmaceutical composition comprised of gatifloxacin
Abstract:There is provided an aqueous liquid pharmaceutical composition which comprises Gatifloxacin (chemical nomenclature: (.+-.)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazi nyl)-4-oxo-3-quinoline carboxylic acid) or its salt and disodium edetate. Further, there are provided a method for raising corneal permeability of Gatifloxacin, a method for preventing precipitation of Gatifloxacin crystals, and a method for preventing coloration of Gatifloxacin by incorporating disodium edetate into an aqueous liquid preparation containing Gatifloxacin or its salt.
Inventor(s): Yasueda; Shinichi (Kobe, JP), Inada; Katsuhiro (Kobe, JP)
Assignee: Senju Pharmaceutical Co., Ltd. (Osaka, JP) Kyorin Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:09/529,882
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Use;

Drugs Protected by US Patent 6,333,045

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan ZYMAR gatifloxacin SOLUTION/DROPS;OPHTHALMIC 021493-001 Mar 28, 2003 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,333,045

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan10/235432Aug 21, 1998
PCT Information
PCT FiledAugust 20, 1999PCT Application Number:PCT/JP99/04483
PCT Publication Date:March 02, 2000PCT Publication Number: WO00/10570

International Patents Family Members for US Patent 6,333,045

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
South Korea 20010031240 ➤ Try a Free Trial
Japan 5138128 ➤ Try a Free Trial
Hong Kong 1029934 ➤ Try a Free Trial
Spain 2264266 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Healthtrust
Merck
McKesson
Daiichi Sankyo
Johnson and Johnson
Fish and Richardson
Covington
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.